The Patent Eligibility of Bioprint Technology under the United States Patent System
| Autor: | Chanchart Chotiphol, 陳俊龍 |
|---|---|
| Rok vydání: | 2018 |
| Druh dokumentu: | 學位論文 ; thesis |
| Popis: | 106 Bioprint is an umbrella term covering a new branch of biotechnology, with one of the most intriguing feature being the ability to artificially synthesize human tissues and organs on demand. With such capability, many are hoping that the Bioprint Technology will be able to address the current organs shortage, while also providing support to future medical researches. Essentially, the advantageous features of the Bioprint Technology have not gone unnoticed, as such for-profit firms and private institutions are eager to quickly obtain IP protections and the temporary monopoly rights to this valuable piece of technology. Despite the many capabilities, high demand and rapid advancement, the legal system have been slow to keep up. Even though, the intellectual property law was especially created to manage and protect new technological inventions alike Bioprint Technology, but history have shown that biotechnology related inventions often bring about disputes with famous examples including: Diamond v. Chakrabarty, AMP v. Myriad or Mayo v. Prometheus. Under this theory, the issue of patent eligibility for Bioprint Technology still remain highly questionable. Although, the USPTO have already granted a good amount of patents relating to the Bioprint Technology but the legal validity is still yet to be properly defined. With the patent eligibility issues in mind, this dissertation is aimed to provide the readers with a broad overview of the Bioprint Technology, then proceed to analyze the patent eligibility of the technology within the scope of the United States Patent System, Leahy–Smith America Invents Act (AIA), and with reference to past related cases. |
| Databáze: | Networked Digital Library of Theses & Dissertations |
| Externí odkaz: |
|